L.V. Prasad Eye Institute Observes Retinoblastoma Awareness Week From May 10-16

Retinoblastoma is the most common type of childhood eye cancer affecting one in 15,000 to 18,000 live births. Its causes can be both hereditary and non-hereditary.

To create awareness about Retinoblastoma, L V Prasad Eye Institute (LVPEI), Hyderabad (capital of the southern Indian state of Telangana) will observe 8th World Retinoblastoma Awareness Week from May 10 to 16.

Retinoblastoma - Causes, Symptoms, Diagnosis, Treatment & Prevention
Retinoblastoma is a type of cancer of the eye occurring in children. Early diagnosis and treatment, and genetic counselling can go a long way in saving life and vision in children and siblings at risk for this disease.

About 90% of children with retinoblastoma are diagnosed before 5 years of age. More than 8000 new cases of retinoblastoma are detected every year worldwide, with over 1000 new cases in India.

LVPEI treats about 150 to 200 cases every year, of which 5 to 10 percent are in late stages. Retinoblastoma is curable if the tumour is detected early. Early diagnosis can help save the eye through chemotherapy and focal treatment, thus saving the life, eye, and the vision of the child.

Dr Swathi Kaliki, consultant ocular oncologist, LVPEI, said the institute would provide best possible holistic clinical care and cutting-edge treatment to the patients with retinoblastoma.

Adult Survivors of Childhood Eye Cancer Experience Few Cognitive Setbacks
Adult survivors of retinoblastoma, a type of eye cancer that usually develops in early childhood, have few cognitive or social problems, finds a new study.

“Retinoblastoma can be cured completely, if detected early. But in advanced stages life can be saved but chances of salvaging the eye is bleak,” Dr Kaliki said.

Facial Prosthesis Offers New Hope for Eye Cancer Patients
Using facial scanning software and 3-D printing, researchers have developed a fast and inexpensive way to make facial prostheses for eye cancer patients.

Source-Medindia

Survival Time for Treatments of Rare Eye Cancer Compared in New Study
In patients with advanced uveal melanoma treatment with the agent selumetinib compared with chemotherapy resulted in an improved cancer progression-free survival time and tumor response rate.